CAMBIUM BIO LIMITED - Announcements

2.44%

40.0¢

Market Cap $7.313M

Healthcare Biotechnology

Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage... Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

CMB	Regeneus partners with a leading animal health company	PRICE SENSITIVE	02/11/15	189.07KB	Share
CMB	First patient safely treated in cancer vaccine trial	PRICE SENSITIVE	27/10/15	188.72KB	Share
CMB	Appendix 4G and Corporate Governance Statement		19/10/15	1.78MB	Share
CMB	Annual Report 2015		19/10/15	944.36KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	15/10/15	1001.26KB	Share
CMB	Regeneus receives R&D tax incentive refund of $3.4m	PRICE SENSITIVE	13/10/15	176.76KB	Share
CMB	Notice of Annual General Meeting / Proxy Form		08/10/15	3.04MB	Share
CMB	Appendix 3B - Restricted securities released from escrow		22/09/15	474.49KB	Share
CMB	Restricted Securities to be released from escrow		04/09/15	25.48KB	Share
CMB	Date of AGM		02/09/15	125.48KB	Share
CMB	FY15 Full-Year Results and Business Update Presentation		31/08/15	3.74MB	Share
CMB	FY15 Full-Year Results and Business Update Announcement		31/08/15	204.99KB	Share
CMB	FY15 Preliminary Final Report	PRICE SENSITIVE	31/08/15	2.77MB	Share
CMB	First patient treated in Progenza stem cell trial	PRICE SENSITIVE	10/08/15	193.5KB	Share
CMB	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/15	204.73KB	Share
CMB	Appendix 3Y - Dr Roger Aston		04/06/15	93.06KB	Share
CMB	Approval for personalised cancer immunotherapy trial	PRICE SENSITIVE	25/05/15	194.95KB	Share
CMB	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/15	203.49KB	Share
CMB	Regeneus receives approval for Progenza OA trial	PRICE SENSITIVE	22/04/15	197.44KB	Share
CMB	Achievement of key stem cell manufacturing milestone	PRICE SENSITIVE	07/04/15	202.44KB	Share
CMB	Appendix 3X - Dr Glen Richards		01/04/15	74.29KB	Share
CMB	RGS to present at Regenerative Medicine Investor Day		23/03/15	196.6KB	Share
CMB	RGS to present at Regenerative Medicine Investor Day		23/03/15	196.6KB	Share
CMB	Positive preclinical results for Progenza	PRICE SENSITIVE	09/03/15	199.71KB	Share
CMB	New Director joins Regeneus Board of Directors		23/02/15	184.07KB	Share
CMB	Regeneus Half-Year Announcement		19/02/15	195.19KB	Share
CMB	Regeneus Half-Yearly Appendix 4D and Accounts	PRICE SENSITIVE	19/02/15	626.85KB	Share
CMB	Appendix 4C - Q2 FY15	PRICE SENSITIVE	30/01/15	192.88KB	Share
CMB	Patent granted for protecting cryopreserved stem cells	PRICE SENSITIVE	19/12/14	193.87KB	Share
CMB	New Japanese laws to fast track cell therapy take effect	PRICE SENSITIVE	26/11/14	199.96KB	Share
CMB	Regeneus concludes strategic review	PRICE SENSITIVE	24/11/14	196.91KB	Share
CMB	Acne treatment patent granted	PRICE SENSITIVE	14/11/14	202.7KB	Share
CMB	Board and Management Changes	PRICE SENSITIVE	10/11/14	200.88KB	Share
CMB	Appendix 3B - Issue of Shares		06/11/14	507.99KB	Share
CMB	Subscription for shares and options by Directors		06/11/14	543.61KB	Share
CMB	Appendix 4C - Q1 FY2015	PRICE SENSITIVE	29/10/14	122.17KB	Share
CMB	Results of Annual General Meeting		28/10/14	482.42KB	Share
CMB	Presentation to Shareholders at AGM 2014		28/10/14	3.39MB	Share
CMB	Chairman's Address to Shareholders		28/10/14	194.56KB	Share
CMB	Response to 7.30 media commentary	PRICE SENSITIVE	09/10/14	231.7KB	Share
CMB	Trading Halt	PRICE SENSITIVE	07/10/14	137.47KB	Share
CMB	Notice of Annual General Meeting/Proxy Form		25/09/14	3.88MB	Share
CMB	RGS receives R&D tax incentive refund of $3.7m	PRICE SENSITIVE	25/09/14	181.84KB	Share
CMB	HiQCell Regenerative Medicine Clinic to open in Singapore	PRICE SENSITIVE	23/09/14	212.75KB	Share
CMB	Kvax cancer vaccine available in Australia, US trial begins	PRICE SENSITIVE	11/09/14	218.6KB	Share
CMB	Appendix 3B - Issue of Shares		10/09/14	462.38KB	Share
CMB	Share Purchase Plan closes oversubscribed		09/09/14	185.36KB	Share
CMB	Date of AGM		29/08/14	126.95KB	Share
CMB	AFL approves use of Regeneus' stem cell therapy, HiQCell	PRICE SENSITIVE	27/08/14	191.7KB	Share
CMB	Annual Report for the year ended 30 June 2014		25/08/14	861.96KB	Share
CMB	Appendix 4E - 30 June 2014	PRICE SENSITIVE	25/08/14	170.99KB	Share
CMB +CTE	Regeneus and Cryosite Partnership		21/08/14	203.1KB	Share
CTE +CMB	Cryosite Regeneus partnership	PRICE SENSITIVE	21/08/14	162.95KB	Share
CMB	Share Purchase Plan		19/08/14	2.74MB	Share
CMB	Patient Registry Update	PRICE SENSITIVE	19/08/14	234.83KB	Share
CMB	Appendix 3B - Issue of Options		15/08/14	570.61KB	Share
CMB	Appendix 3B - Issue of Shares		15/08/14	572.1KB	Share
CMB	Successful $3M private placement & Cleansing Notice	PRICE SENSITIVE	15/08/14	104.77KB	Share
CMB	ASX Listing Rule 3.10.3 Notice		11/08/14	262.04KB	Share
CMB	RGS raises capital through Placement and SPP	PRICE SENSITIVE	08/08/14	212.2KB	Share
CMB	Trading Halt	PRICE SENSITIVE	06/08/14	92.17KB	Share
CMB	Appendix 4C - Q4 FY14	PRICE SENSITIVE	31/07/14	205.52KB	Share
CMB	RGS Product Pipeline Update	PRICE SENSITIVE	31/07/14	305.86KB	Share
CMB	Exclusive global rights for human cancer vaccine-Amended hdr		08/07/14	203.97KB	Share
CMB	Disclosure Document	PRICE SENSITIVE	08/07/14	203.97KB	Share
CMB	RGS enters into agreement for US marketing trial for Kvax	PRICE SENSITIVE	30/06/14	198.26KB	Share
CMB	New treatment option for chronic neuropathic pain patients	PRICE SENSITIVE	14/05/14	201.61KB	Share
CMB	Appendix 4C - quarterly	PRICE SENSITIVE	17/04/14	209.62KB	Share
CMB	Ethics approval for procurement for off-the-shelf treatment	PRICE SENSITIVE	08/04/14	188.59KB	Share
CMB	Regeneus partners with Hennessy Research for Kvax	PRICE SENSITIVE	04/04/14	200.28KB	Share
CMB	HiQCell Joint Registry Results	PRICE SENSITIVE	26/03/14	328.25KB	Share
CMB	RGS to present at Regenerative Medicine Investor Day		21/03/14	187.35KB	Share
CMB	Appendix 3B		19/03/14	462.12KB	Share
CMB	Change of Registered Address		10/03/14	160.22KB	Share
CMB	Kvax cancer vaccine paper shows safety and efficacy	PRICE SENSITIVE	06/03/14	213.79KB	Share
CMB	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/14	6.07MB	Share
CMB	Appendix 3B		07/02/14	488.13KB	Share
CMB	Appendix 4C - Q2 FY14	PRICE SENSITIVE	31/01/14	228.75KB	Share
CMB	Regeneus partners with Lonza for Canine CryoShot	PRICE SENSITIVE	22/01/14	189.44KB	Share
CMB	Appendix 3B		17/01/14	309.03KB	Share
CMB	Regeneus (RGS) results of AGM - 27 November 2013		27/11/13	209.37KB	Share
CMB	Chairman's Address at Regeneus AGM - November 2013		27/11/13	209.04KB	Share
CMB	Regeneus to fast-track human cells under new Japanese laws		25/11/13	190.6KB	Share
CMB	Presentation at BBY Life Sciences Conference - November 2013		19/11/13	869.25KB	Share
CMB	Presentation at BBY Life Sciences Conference Covering Letter		19/11/13	180.84KB	Share
CMB	Press Release re Novel canine cancer vaccine	PRICE SENSITIVE	14/11/13	194.7KB	Share
CMB	HiQCell stem cell therapy now available in Melbourne		30/10/13	195.63KB	Share
CMB	Investor presentation - ASX Spotlight Conference, Singapore		29/10/13	1.45MB	Share
CMB	Investor presentation - ASX Spotlight Conference, Singapore		29/10/13	178.68KB	Share
CMB	Annual Report to shareholders		29/10/13	1.85MB	Share
CMB	Notice of Annual General Meeting Proxy Form		25/10/13	260.71KB	Share
CMB	Notice of Annual General Meeting		25/10/13	294.95KB	Share
CMB	Amended Appendix 4C		22/10/13	190.13KB	Share
CMB	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/13	199.17KB	Share
CMB	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/13	229.37KB	Share
CMB	Becoming a substantial holder		14/10/13	312.88KB	Share
CMB	Progress Report	PRICE SENSITIVE	08/10/13	241.72KB	Share
CMB	Full Year Statutory Accounts		30/09/13	1.13MB	Share
CMB	Initial Director's Interest Notice		24/09/13	103.58KB	Share
CMB	Initial Director's Interest Notice		24/09/13	102.51KB	Share

CMB Regeneus partners with a leading animal health company
02/11/15	PRICE SENSITIVE	189.07KB	Share
CMB First patient safely treated in cancer vaccine trial
27/10/15	PRICE SENSITIVE	188.72KB	Share
CMB Appendix 4G and Corporate Governance Statement
19/10/15		1.78MB	Share
CMB Annual Report 2015
19/10/15		944.36KB	Share
CMB Appendix 4C - Quarterly
15/10/15	PRICE SENSITIVE	1001.26KB	Share
CMB Regeneus receives R&D tax incentive refund of $3.4m
13/10/15	PRICE SENSITIVE	176.76KB	Share
CMB Notice of Annual General Meeting / Proxy Form
08/10/15		3.04MB	Share
CMB Appendix 3B - Restricted securities released from escrow
22/09/15		474.49KB	Share
CMB Restricted Securities to be released from escrow
04/09/15		25.48KB	Share
CMB Date of AGM
02/09/15		125.48KB	Share
CMB FY15 Full-Year Results and Business Update Presentation
31/08/15		3.74MB	Share
CMB FY15 Full-Year Results and Business Update Announcement
31/08/15		204.99KB	Share
CMB FY15 Preliminary Final Report
31/08/15	PRICE SENSITIVE	2.77MB	Share
CMB First patient treated in Progenza stem cell trial
10/08/15	PRICE SENSITIVE	193.5KB	Share
CMB Appendix 4C - quarterly
30/07/15	PRICE SENSITIVE	204.73KB	Share
CMB Appendix 3Y - Dr Roger Aston
04/06/15		93.06KB	Share
CMB Approval for personalised cancer immunotherapy trial
25/05/15	PRICE SENSITIVE	194.95KB	Share
CMB Appendix 4C - quarterly
29/04/15	PRICE SENSITIVE	203.49KB	Share
CMB Regeneus receives approval for Progenza OA trial
22/04/15	PRICE SENSITIVE	197.44KB	Share
CMB Achievement of key stem cell manufacturing milestone
07/04/15	PRICE SENSITIVE	202.44KB	Share
CMB Appendix 3X - Dr Glen Richards
01/04/15		74.29KB	Share
CMB RGS to present at Regenerative Medicine Investor Day
23/03/15		196.6KB	Share
CMBRGS to present at Regenerative Medicine Investor Day
23/03/15		196.6KB	Share
CMB Positive preclinical results for Progenza
09/03/15	PRICE SENSITIVE	199.71KB	Share
CMB New Director joins Regeneus Board of Directors
23/02/15		184.07KB	Share
CMB Regeneus Half-Year Announcement
19/02/15		195.19KB	Share
CMB Regeneus Half-Yearly Appendix 4D and Accounts
19/02/15	PRICE SENSITIVE	626.85KB	Share
CMB Appendix 4C - Q2 FY15
30/01/15	PRICE SENSITIVE	192.88KB	Share
CMB Patent granted for protecting cryopreserved stem cells
19/12/14	PRICE SENSITIVE	193.87KB	Share
CMB New Japanese laws to fast track cell therapy take effect
26/11/14	PRICE SENSITIVE	199.96KB	Share
CMB Regeneus concludes strategic review
24/11/14	PRICE SENSITIVE	196.91KB	Share
CMB Acne treatment patent granted
14/11/14	PRICE SENSITIVE	202.7KB	Share
CMB Board and Management Changes
10/11/14	PRICE SENSITIVE	200.88KB	Share
CMB Appendix 3B - Issue of Shares
06/11/14		507.99KB	Share
CMB Subscription for shares and options by Directors
06/11/14		543.61KB	Share
CMB Appendix 4C - Q1 FY2015
29/10/14	PRICE SENSITIVE	122.17KB	Share
CMB Results of Annual General Meeting
28/10/14		482.42KB	Share
CMB Presentation to Shareholders at AGM 2014
28/10/14		3.39MB	Share
CMB Chairman's Address to Shareholders
28/10/14		194.56KB	Share
CMB Response to 7.30 media commentary
09/10/14	PRICE SENSITIVE	231.7KB	Share
CMB Trading Halt
07/10/14	PRICE SENSITIVE	137.47KB	Share
CMB Notice of Annual General Meeting/Proxy Form
25/09/14		3.88MB	Share
CMB RGS receives R&D tax incentive refund of $3.7m
25/09/14	PRICE SENSITIVE	181.84KB	Share
CMB HiQCell Regenerative Medicine Clinic to open in Singapore
23/09/14	PRICE SENSITIVE	212.75KB	Share
CMB Kvax cancer vaccine available in Australia, US trial begins
11/09/14	PRICE SENSITIVE	218.6KB	Share
CMB Appendix 3B - Issue of Shares
10/09/14		462.38KB	Share
CMB Share Purchase Plan closes oversubscribed
09/09/14		185.36KB	Share
CMB Date of AGM
29/08/14		126.95KB	Share
CMB AFL approves use of Regeneus' stem cell therapy, HiQCell
27/08/14	PRICE SENSITIVE	191.7KB	Share
CMB Annual Report for the year ended 30 June 2014
25/08/14		861.96KB	Share
CMB Appendix 4E - 30 June 2014
25/08/14	PRICE SENSITIVE	170.99KB	Share
CMB +CTE Regeneus and Cryosite Partnership
21/08/14		203.1KB	Share
CTE +CMB Cryosite Regeneus partnership
21/08/14	PRICE SENSITIVE	162.95KB	Share
CMB Share Purchase Plan
19/08/14		2.74MB	Share
CMB Patient Registry Update
19/08/14	PRICE SENSITIVE	234.83KB	Share
CMB Appendix 3B - Issue of Options
15/08/14		570.61KB	Share
CMB Appendix 3B - Issue of Shares
15/08/14		572.1KB	Share
CMB Successful $3M private placement & Cleansing Notice
15/08/14	PRICE SENSITIVE	104.77KB	Share
CMB ASX Listing Rule 3.10.3 Notice
11/08/14		262.04KB	Share
CMB RGS raises capital through Placement and SPP
08/08/14	PRICE SENSITIVE	212.2KB	Share
CMB Trading Halt
06/08/14	PRICE SENSITIVE	92.17KB	Share
CMB Appendix 4C - Q4 FY14
31/07/14	PRICE SENSITIVE	205.52KB	Share
CMB RGS Product Pipeline Update
31/07/14	PRICE SENSITIVE	305.86KB	Share
CMB Exclusive global rights for human cancer vaccine-Amended hdr
08/07/14		203.97KB	Share
CMB Disclosure Document
08/07/14	PRICE SENSITIVE	203.97KB	Share
CMB RGS enters into agreement for US marketing trial for Kvax
30/06/14	PRICE SENSITIVE	198.26KB	Share
CMBNew treatment option for chronic neuropathic pain patients
14/05/14	PRICE SENSITIVE	201.61KB	Share
CMBAppendix 4C - quarterly
17/04/14	PRICE SENSITIVE	209.62KB	Share
CMBEthics approval for procurement for off-the-shelf treatment
08/04/14	PRICE SENSITIVE	188.59KB	Share
CMBRegeneus partners with Hennessy Research for Kvax
04/04/14	PRICE SENSITIVE	200.28KB	Share
CMBHiQCell Joint Registry Results
26/03/14	PRICE SENSITIVE	328.25KB	Share
CMBRGS to present at Regenerative Medicine Investor Day
21/03/14		187.35KB	Share
CMBAppendix 3B
19/03/14		462.12KB	Share
CMBChange of Registered Address
10/03/14		160.22KB	Share
CMBKvax cancer vaccine paper shows safety and efficacy
06/03/14	PRICE SENSITIVE	213.79KB	Share
CMBHalf Yearly Report and Accounts
27/02/14	PRICE SENSITIVE	6.07MB	Share
CMBAppendix 3B
07/02/14		488.13KB	Share
CMBAppendix 4C - Q2 FY14
31/01/14	PRICE SENSITIVE	228.75KB	Share
CMBRegeneus partners with Lonza for Canine CryoShot
22/01/14	PRICE SENSITIVE	189.44KB	Share
CMBAppendix 3B
17/01/14		309.03KB	Share
CMBRegeneus (RGS) results of AGM - 27 November 2013
27/11/13		209.37KB	Share
CMBChairman's Address at Regeneus AGM - November 2013
27/11/13		209.04KB	Share
CMBRegeneus to fast-track human cells under new Japanese laws
25/11/13		190.6KB	Share
CMBPresentation at BBY Life Sciences Conference - November 2013
19/11/13		869.25KB	Share
CMBPresentation at BBY Life Sciences Conference Covering Letter
19/11/13		180.84KB	Share
CMBPress Release re Novel canine cancer vaccine
14/11/13	PRICE SENSITIVE	194.7KB	Share
CMBHiQCell stem cell therapy now available in Melbourne
30/10/13		195.63KB	Share
CMBInvestor presentation - ASX Spotlight Conference, Singapore
29/10/13		1.45MB	Share
CMBInvestor presentation - ASX Spotlight Conference, Singapore
29/10/13		178.68KB	Share
CMBAnnual Report to shareholders
29/10/13		1.85MB	Share
CMBNotice of Annual General Meeting Proxy Form
25/10/13		260.71KB	Share
CMBNotice of Annual General Meeting
25/10/13		294.95KB	Share
CMBAmended Appendix 4C
22/10/13		190.13KB	Share
CMBAppendix 4C - quarterly
21/10/13	PRICE SENSITIVE	199.17KB	Share
CMBAppendix 4C - quarterly
21/10/13	PRICE SENSITIVE	229.37KB	Share
CMBBecoming a substantial holder
14/10/13		312.88KB	Share
CMBProgress Report
08/10/13	PRICE SENSITIVE	241.72KB	Share
CMBFull Year Statutory Accounts
30/09/13		1.13MB	Share
CMBInitial Director's Interest Notice
24/09/13		103.58KB	Share
CMBInitial Director's Interest Notice
24/09/13		102.51KB	Share

REFRESH

First 2 3 4 5

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 40.0¢		Change -0.010(2.44%)		Mkt cap ! $7.313M

Open	High	Low	Value	Volume
41.0¢	41.0¢	40.0¢	$1.181K	2.912K

Buyers (Bids)

No.	Vol.	Price($)
1	1500	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
41.0¢	2441	1

View Market Depth

No.	Vol.	Price($)
1	1500	0.370
1	10000	0.340
1	20000	0.280
1	25000	0.270
1	9883	0.260

Price($)	Vol.	No.
0.410	2441	1
0.445	30	1
0.450	6000	1
0.455	550	1
0.480	4936	1

Last trade - 16.10pm 12/08/2025 (20 minute delay)

CMB (ASX) Chart

CAMBIUM BIO LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available